Exp Clin Endocrinol Diabetes 2001; 109(8): 393-396
DOI: 10.1055/s-2001-18991
Articles

© Johann Ambrosius Barth

Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes

K. Raile1 , V. Noelle1 , R. Landgraf2 , H. P. Schwarz1
  • 1 Children's Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
  • 2 Department of Internal Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
Further Information

Publication History

Publication Date:
13 December 2001 (online)

Summary:

Aim: To evaluate clinical and immunological factors that are associated with lipodystrophy, i.e. lipoatrophy and lipohypertrophy, in diabetic children and adolescents. - Methods: We investigated in a cross-sectional study 112 children and adolescents (age 1.1-19.1 yrs.) with type 1 diabetes. To grade lipodystrophy, we developed a clinical score ranging from normal (grade 0), moderate hypertrophy of subcutaneous tissue (grade 1), severe hypertrophy with increased density of tissue (grade 2) to lipoatrophy (grade 3). In all children, grade of lipodystrophy, antibodies against insulin (IA) or beta cell antigens (IA-2 and GAD) and clinical parameters were documented. - Results: The antibodies against insulin (IA) increased significantly after diabetes manifestation and initiation of insulin treatment, while beta cell specific antibodies (IA-2, GAD) did not. Lipoatrophy (grade 3) was seen in 4 children, severe lipohypertrophy (grade 2) in 18 and moderate lipohypertrophy (grade 1) in 27 children. No alteration of injection sites was found in 63 children. Amongst clinical and immunological parameters, IA levels were significantly associated with hypertrophy or atrophy of injection sites. - Conclusion: The strong association of lipoatrophy and lipohypertrophy with insulin antibodies might suggest that autoimmune phenomena with insulin play a role in the development of both. Despite an association of IA and lipodystrophy in type 1 diabetic children, the causal link between the two remains unproven and requires further longitudinal exploration.

References

  • 1 Atlan-Gepner C, Bongrand P, Farnarier C, Xerri L, Choux R, Gauthier J F, Brue T, Vague P, Grob J J, Vialettes B. Diabetes Care 19 1283-1285 1996; 
  • 2 Chantelau E, Reuter M, Schotes S. et al. . Severe lipoatrophy with human insulin: successfully treated by CSII (letter).  Exp Clin Endocrinol. 101 580-581 1993; 
  • 3 Fuchtenbusch M, Kredel K, Bonifacio E. et al. . Exposure to exogenous insulin promotes IgG1 and the T-helper 2-associated IgG4 responses to insulin but not to other islet autoantigens.  Diabetes. 49 918-925 2000; 
  • 4 Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors.  Exp Clin Endocrinol Diabetes. 104 106-110 1996; 
  • 5 Holl RW. Computer programs and data sheets. Initiative on equality control of the German Working-Group on Pediatric Diabetology.  Horm Res 50 (S 1) 68-73 1998; 
  • 6 Perez M, Kohn S. Cutaneous manifestations of diabetes mellitus.  J Amer Acad Derm. 30 519-531 1994; 
  • 7 Reeves W G, Allen B R, Tattersall R B. Insulin-induced lipoatrophy: evidence for an immune pathogenesis.  Br Med J. 280 1500-1503 1980; 
  • 8 Thow J C, Johnson A B, Marsden S. et al. . Morphology of palpably abnormal injection sites and effects on absorption of isophane (NPH) insulin.  Diabetic Medicine. 7 795-799 1990; 
  • 9 Young R J, Hannan W J, Frier B M. et al. . Diabetic lipohypertrophy delays insulin absorption.  Diabetes Care. 7 479-480 1984; 
  • 10 Ziegler A G, Ziegler R, Vardi P, Jackson R A, Soeldner J S, Eisenbarth G S. Life-table analysis of progression to diabetes of anti-insulin antibody-positive relatives of individuals with type I diabetes.  Diabetes. 40 709-714 1989; 

M.D. Klemens Raile

University Children's Hospital

Oststr. 21-25

D-04317 Leipzig

Germany

Phone: + 49-3 41-2 60 00

Fax: + 49-3 41-2 60 09

Email: raik@medizin.uni-leipzig.de

    >